Latest Regulatory Progress News

Neurotech International has locked in a $3.15 million secured loan against its anticipated R&D tax incentives to fund pivotal Phase III autism trials and ongoing operations.

Ora Banda Mining (ASX:OBM) reported a substantial expansion of its Mineral Resources and Ore Reserves at the Davyhurst Gold Project, driven by exploration success and significant drilling investment.

Resolution Minerals has completed 16 diamond core holes totalling 4,470 metres at its Golden Gate South prospect in Idaho, progressing one third of its 2026 drill program aimed at defining gold and tungsten mineralisation.

OncoSil Medical has completed key manufacturing validation cycles with Cyclotek, paving the way for scalable Australian production of its OncoSil™ device. With a $2.1 million capital investment, the company aims to boost margins and supply chain control ahead of commercial launch in late 2026.

Sky Metals has unveiled a significant Mineral Resource Estimate upgrade for its Tallebung project, lifting tin and tungsten inventories substantially and introducing a maiden silver resource. This positions Tallebung as a large-scale, shallow open-pit opportunity with promising metallurgical and development prospects.

Infini Resources has completed a high-resolution airborne radiometric survey at its Portland Creek Uranium Project in Newfoundland, enhancing geological targeting ahead of a planned Phase 3 diamond drilling campaign in Q3 2026.

Noxopharm has taken a key regulatory step by requesting a pre-IND meeting with the US FDA for its autoimmune drug candidate SOF-SKN, aiming to smooth the path for clinical development and boost its commercial appeal.

Lakes Blue Energy is positioning its Wombat Gas Project as a key contributor to Victoria's energy security and emerging AI infrastructure, with a conceptual study projecting a post-tax NPV10 of A$605 million and first gas in early 2029.

Algorae Pharmaceuticals has been appointed as a supplier under a NSW Health public hospital supply contract, marking a strategic milestone despite uncertain immediate revenue impact.

OncoSil Medical secures a spot in the PALACROS consortium, advancing its OncoSil™ device through a cost-efficient Phase II trial targeting unresectable locally advanced pancreatic cancer.

Kinetiko Energy has approved a Field Development Plan marking its shift from exploration to production at the Brakfontein gas project in South Africa, aiming to fast-track gas output and secure strategic funding.

Imugene Limited reports a complete response in the first patient treated with azer-cel combined with BTK inhibitors in its Phase 1b trial, highlighting potential for resistant follicular lymphoma.